semaglutide bowel obstruction class action in dallas a randomized trial of over 1400 participants with BMI ≥30 kg/m2, those assigned to weekly subcutaneous 7.2 mg lost about 3 percent more of their body weight after 72 weeks Thousands of lawsuits are being

GLP-1 receptor agonists commonly cause diarrhea due to delayed gastric emptying, increased intestinal transit time, altered gut microbiota composition, and p...

Methods In this open-label, single-center, casecontrol pilot study, patients with IIH (pwIIH) and a body mass index (BMI) of30 kg/m2 were offered to receive a GLP-1-RA (semaglutide, liraglutide) in addition to the usual care weight management (UCWM)

Administration of SEMA improved liver function as demonstrated by the reduction in the plasma levels of aminotransferases and gamma-glutamyl transpeptidase (GGT) along with the rise in serum albumin level

Additionally, the loss of fatty acids can affect the skin barrier, leading to dryness and a lacklustre appearance

Key Takeaways Clinical trials indicate that retatrutide typically results in more rapid and significant weight loss than semaglutide, particularly during the early and midterm stages of treatment